Drug intelligence / Profile preview

ChAd63-MVA CS

Development stage: Phase 2
Lead developer: University of Oxford
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ChAd63-MVA CS is a viral-vectored malaria vaccine candidate that uses a heterologous prime-boost regime to target the circumsporozoite protein (CS) of Plasmodium falciparum. It consists of two components: ChAd63 CS (a replication-deficient chimpanzee adenovirus 63 vector) and MVA CS (a modified vaccinia virus Ankara vector), both expressing the CS antigen. This vaccine platform aims to induce both strong T-cell responses and antibody responses against the CS protein, which is a key antigen found on the surface of malaria sporozoites.

Other names: chimpanzee adenovirus 63 circumsporozoite protein vaccine + modified vaccinia virus Ankara circumsporozoite protein vaccine

Targets

CSP (Circumsporozoite protein)

Beyond the preview

Go deeper on ChAd63-MVA CS.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ChAd63-MVA CS.

Explore the full profile